Vaccination against Sars-CoV-2 works well during cancer therapy for solid tumors
Most patients with cancer receiving immunotherapy, chemotherapy, or both as treatment for solid tumors respond well to vaccination against against Sars-CoV-2, the pandemic coronavirus.
A study performed in the UMCG in Groningen, Erasmus Universiteit Rotterdam, and the The Netherlands Cancer Institute, in collaboration with the Dutch RIVM National Institute for Public Health and the Environment and the Netherlands Comprehensive Cancer Organisation (IKNL (Integraal Kankercentrum Nederland)), shows that vaccination of patients being treated for a solid tumor is safe and often effective. These results were presented at the European Society of Medical Oncology annual congress and will be published in The Lancet Oncology, both on 20 September.
IKNL is a proud partner in this study. Our clinical trials office provides project management, central and local data management for this study called the VOICE-study.
Read more about the findings on the website of the University Medical Centre Groningen.